{
    "name": "ceftazidime",
    "comment": "Rx",
    "other_names": [
        "Fortaz",
        "Tazicef",
        "Tazidime"
    ],
    "classes": [
        "Cephalosporins",
        "3rd Generation"
    ],
    "source": "https://reference.medscape.com/drug/fortaz-tazicef-ceftazidime-342507",
    "pregnancy": {
        "common": [
            "Pregnancy category: B",
            "Lactation: Drug excreted in breast milk; use with caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Drug excreted in breast milk; use with caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Documented hypersensitivity to drug or excipients, or to cephalosporin class of antibacterial drugs, penicillins or other beta-lactam antibacterial drugs"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "High and prolonged serum ceftazidime concentrations can occur from usual dosages in patients with transient or persistent reduction of urinary output because of renal insufficiency; elevated levels of the drug in these patients can lead to, seizures, nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonus reported in patients treated with ceftazidime; adjust dosing based on creatinine clearance in patients with renal impairment",
                "Elevated international normalized ratio (INR) has reported in patients with nutritional deficiency, prolonged treatment, or renal or hepatic disease",
                "Use with caution in patients with history of seizure disorder (especially in renal impairment, where drug levels may increase significantly)",
                "Modify dose in renal impairment",
                "Use with caution in patients with history of penicillin allergy",
                "Prescribing the drug in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria"
            ],
            "specific": [
                {
                    "type": "Clostridioides difficile-associated diarrhea",
                    "description": [
                        "Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including ceftazidime products, and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile",
                        "C. difficile produces toxins A and B, which contribute to the development of CDAD; hypertoxin- producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy",
                        "CDAD must be considered in all patients who present with diarrhea following antibacterial use; careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents",
                        "If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued; appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "ceftazidime decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "ceftazidime, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "microbiota oral",
            "description": {
                "common": "ceftazidime decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "ceftazidime decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bazedoxifene/conjugated estrogens",
            "description": {
                "common": "ceftazidime will decrease the level or effect of bazedoxifene/conjugated estrogens by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dienogest/estradiol valerate",
            "description": {
                "common": "ceftazidime will decrease the level or effect of dienogest/estradiol valerate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. An alternate or additional form of birth control may be advisable during concomitant use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estradiol",
            "description": {
                "common": "ceftazidime will decrease the level or effect of estradiol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estropipate",
            "description": {
                "common": "ceftazidime will decrease the level or effect of estropipate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "ceftazidime will decrease the level or effect of ethinylestradiol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate",
            "description": {
                "common": "ceftazidime will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "probenecid",
            "description": {
                "common": "probenecid will increase the level or effect of ceftazidime by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "ceftazidime decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, ceftazidime.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "ceftazidime increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acyclovir",
            "description": {
                "common": "ceftazidime will increase the level or effect of acyclovir by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aminohippurate sodium",
            "description": {
                "common": "ceftazidime will increase the level or effect of aminohippurate sodium by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin",
            "description": {
                "common": "ceftazidime will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "ceftazidime will increase the level or effect of aspirin rectal by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "ceftazidime will increase the level or effect of aspirin/citric acid/sodium bicarbonate by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol decreases effects of ceftazidime by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "ceftazidime will increase the level or effect of choline magnesium trisalicylate by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "furosemide",
            "description": {
                "common": "ceftazidime increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rose hips",
            "description": {
                "common": "rose hips will increase the level or effect of ceftazidime by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "ceftazidime will increase the level or effect of salicylates (non-asa) by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "ceftazidime will increase the level or effect of sulfasalazine by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "willow bark",
            "description": {
                "common": "ceftazidime will increase the level or effect of willow bark by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Transient increases in transaminases",
            "percent": "3-9"
        },
        {
            "name": "Eosinophilia",
            "percent": "7"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "Immune hypersensitivity reaction",
            "percent": "2"
        },
        {
            "name": "Phlebitis",
            "percent": "2"
        },
        {
            "name": "Rash",
            "percent": "2"
        },
        {
            "name": "maculopapular or erythematous",
            "percent": "2"
        },
        {
            "name": "Thrombocytosis",
            "percent": "1"
        },
        {
            "name": "Injection site pain",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "Asterixis",
            "percent": null
        },
        {
            "name": "Coma",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Encephalopathy",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Hallucinations",
            "percent": null
        },
        {
            "name": "Increased serum concentrations of bilirubin",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Lymphocytosis",
            "percent": null
        },
        {
            "name": "Metallic taste",
            "percent": null
        },
        {
            "name": "Myoclonia",
            "percent": null
        },
        {
            "name": "Nausea or vomiting",
            "percent": null
        },
        {
            "name": "Neuromuscular excitability",
            "percent": null
        },
        {
            "name": "Neutropenia",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Photosensitivity",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Transient increases in blood urea nitrogen",
            "percent": null
        },
        {
            "name": "BUN",
            "percent": null
        },
        {
            "name": "or serum creatinine",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        }
    ]
}